Adipocyte Fatty Acid Binding Protein (A-FABP) as a Potential New Therapeutic Target for the Treatment of Obesity-Associated Cancers

被引：10

作者：

Majchrzak, Kinga ^{[1
]}

Piotrowska, Marta ^{[1
]}

Krajewska, Julia ^{[1
]}

Fichna, Jakub ^{[1
]}

机构：

[1] Med Univ Lodz, Fac Med, Dept Biochem, Lodz, Poland

来源：

CURRENT DRUG TARGETS | 2022年 / 23卷 / 06期

关键词：

Fatty acid binding proteins; adipocytes; cancer; obesity; metabolic syndrome; metabolism; METABOLIC SYNDROME; PROGRESSION; EXPRESSION; MECHANISMS; BIOMARKER; ATHEROSCLEROSIS; METASTASIS; DISEASE; BLADDER; GAMMA;

D O I：

10.2174/1389450122666210712193654

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Fatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regulating metabolism in obese people. Recent studies in mouse models and humans demonstrated the role of A-FABP in increasing the risk of obesity-related cancers. Here we summarized the state of research on the link between obesity, cancer and A-FABP as a new potential therapeutic target for the treatment of obesity - associated cancers.

引用

页码：597 / 605

页数：9

共 46 条

[1]

[Anonymous], 2018, Physiol Behav, V176, P139

[2] A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells [J].